Fortress Biotech Inc. (FBIO)
NASDAQ: FBIO
· Real-Time Price · USD
1.72
0.06 (3.61%)
At close: May 15, 2025, 10:22 AM
Fortress Biotech Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Accutane Revenue | 19.41M | 20.17M | 18.37M | 10.05M |
| Accutane Revenue Growth | -3.77% | +9.77% | +82.76% | n/a |
| Amzeeq Revenue | 5.01M | 6.2M | 7.24M | 17.06M |
| Amzeeq Revenue Growth | -19.22% | -14.37% | -57.54% | n/a |
| Qbrexza Revenue | 25.11M | 25.41M | 26.71M | n/a |
| Qbrexza Revenue Growth | -1.16% | -4.88% | n/a | n/a |
| Zilxi Revenue | 1.64M | 1.96M | 2.27M | n/a |
| Zilxi Revenue Growth | -16.26% | -13.68% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 26.86M | 21.99M | 20.82M | 17.94M | 19.14M | 21.73M | 24.44M | 25.34M | 28.2M | 30.14M | 29.05M | 26.27M | 27.7M | 22.22M | 19.38M | 17.54M | 15.81M | 15.38M | 14.46M | 15.52M | 14.33M | 14.34M | 13.44M | 13.48M | -1.82M | 17.48M | 18.49M | 19.22M | 19.64M | 21.85M | 16.64M | 14.88M | 9.75M | 8.86M | 8.63M | 7.93M | 7.21M | 7.13M | 3.8M | 3.49M |
| Selling, General, and Administrative Revenue Growth | +22.15% | +5.62% | +16.06% | -6.24% | -11.95% | -11.07% | -3.56% | -10.14% | -6.44% | +3.76% | +10.57% | -5.16% | +24.65% | +14.65% | +10.49% | +10.97% | +2.76% | +6.41% | -6.85% | +8.30% | -0.06% | +6.67% | -0.26% | -838.93% | -110.43% | -5.45% | -3.78% | -2.15% | -10.11% | +31.26% | +11.86% | +52.65% | +9.97% | +2.65% | +8.86% | +10.04% | +1.11% | +87.46% | +8.97% | n/a |
| Research and Development Revenue | 9.94M | 9.45M | 12.67M | 24.84M | 14.08M | 20.35M | 32.14M | 39.51M | 35.12M | 29.9M | 33.13M | 36.72M | 43.05M | 28.08M | 33.83M | 20.15M | 17.96M | 13.76M | 17.27M | 15.12M | 23.62M | 15.27M | 18.71M | 23.72M | 25.05M | 19.79M | 17.49M | 25.05M | 14.41M | 16.19M | 13.48M | 8.4M | 10.57M | 8.32M | 8.41M | 7.82M | 5.76M | 10.97M | 3.96M | 9.08M |
| Research and Development Revenue Growth | +5.23% | -25.45% | -48.99% | +76.46% | -30.82% | -36.69% | -18.64% | +12.49% | +17.45% | -9.75% | -9.78% | -14.71% | +53.33% | -17.01% | +67.88% | +12.20% | +30.58% | -20.36% | +14.26% | -36.00% | +54.68% | -18.38% | -21.13% | -5.30% | +26.60% | +13.15% | -30.20% | +73.88% | -11.00% | +20.08% | +60.44% | -20.53% | +27.16% | -1.08% | +7.52% | +35.84% | -47.52% | +177.04% | -56.40% | n/a |